Join our daily newsletter At The Bell to receive exclusive market insights
- Telix Pharmaceuticals has announced the first Australian patient was dosed with TLX250-CDx (TLX) to help with kidney cancer at the Olivia Newton John Cancer and Wellness Centre (ONJ)
- TLX is an antibody-based platform that targets carbonic anhydrase IX (aids in the conversion of carbon dioxide to carbonic acid)
- Telix Pharmaceuticals is up 1.13 per cent today and is currently selling at $1.35 per share
Telix Pharmaceuticals has announced the first Australian patient has been dosed with TLX250-CDx (TLX) to help with kidney cancer at the Olivia Newton John Cancer and Wellness Centre (ONJ).
TLX is being developed by Telix for patients with renal (kidney) cancer using positron emission tomography (PET) imaging.
Current diagnostics includes MRI or CT scans, which are less sensitive and specific for clear cell renal cell carcinoma, the most common kidney cancer.
Other diagnostic methods include the use of ultrasound guided kidney biopsies, which carries a high risk of procedure complication.
TLX is an antibody-based platform that targets carbonic anhydrase IX, which aids in the conversion of carbon dioxide to carbonic acid, and is highly expressed in several serious cancers, including renal, lung and esophageal.
The Australian patient has been added to the Phase III ZIRCON study.
The Zirconium Imaging in Renal Cancer Oncology (ZIRCON) study is an international multi-centre Phase III study at 25 sites in Europe, Australia, Canada and the Unites States.
ZIRCON is a prospective image trial that currently trialing on approximately 250 renal cancer patients undergoing kidney surgery.
“The study determines the sensitivity and specificity of TLX PET imaging to detect clear cell renal cancer in comparison with histologic “ground truth” determined from surgical resection specimens (removal of diseased organ or area),” the announcement stated.
Telix is a global biopharmaceutical company focused on the development of diagnostic and therapeutic products based on targeted radio-pharmaceuticals.
CEO Dr Christian Behrenbrunch is thankful for the staff and patients at the ONJ Centre.
“As a Melbourne-headquartered biotech company it is a privilege to work with world-class clinical sites in our backyard, and the ONJ Center is a very special place to do clinical research,” he said.
Telix Pharmaceuticals is up 1.13 per cent today and is currently selling at $1.35 per share.
